Why Is Bluejay Diagnostics (NASDAQ:BJDX) Dipping 9.24% in Pre-Market Trade on Tuesday?

Vinay Lochav

10 November 2026 11:44 PM AEDT

Why Is Bluejay Diagnostics (NASDAQ:BJDX) Dipping 9.24% in Pre-Market Trade on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Bluejay Diagnostics (NASDAQ:BJDX) is indicated at USD 2.26 pre-market on November 10, 2026, 9.24% under a calculated prior close of USD 2.49, a fall of about USD 0.23 per share.
A 1-for-4 reverse split took effect on November 3, 2026, reducing shares outstanding from about 4.5 million to about 1.1 million under the unchanged BJDX symbol.
Simple arithmetic on 1.1 million shares at USD 2.26 gives a calculated Market Value near USD 2.5 million, a nano-cap scale where small orders move the price.
On a pre-split basis the USD 2.26 quote equals about USD 0.565 per old share, calculated by dividing by 4, and the prior close equals about USD 0.62.

What Moved Bluejay Diagnostics in Pre-Market Trade (down 9.24%)

No company release or filing dated November 9 or November 10, 2026 has been identified in published coverage, so no same-day catalyst is confirmed. The latest confirmed event is the 1-for-4 reverse split approved by the board and effective November 3, 2026, which merged every four common shares into one. Outstanding shares fell from about 4.5 million to about 1.1 million, and the new CUSIP is 095633707. Fractional shares are settled in cash, and the stock still trades on The Nasdaq Capital Market. Published coverage also pointed to quarterly results expected on Friday, November 6, 2026, but no figures were retrieved. At USD 2.26 the quote sits USD 1.26 above the USD 1.00 Nasdaq minimum bid level, calculated. The indicated price of USD 2.26 compares with a calculated Monday close of USD 2.49.

The Reasoning: Reverse Splits and Nano-Cap Dynamics

The release gave no reason for the split and no Nasdaq deficiency details, so the motive is unconfirmed. As general background, companies often use reverse splits to lift the share price above the USD 1.00 minimum bid that Nasdaq requires, yet a split does not change the value of a holding by itself. It only divides the share count by 4 and multiplies the price by 4. Stocks can drift lower after a split when holders who bought the old shares sell, when new financing is anticipated, or when the price simply reverts. A pre-market drop of 9.24% from USD 2.49 to USD 2.26 fits that pattern, though no cause is confirmed here.

Valuation, Liquidity and Risks Around Bluejay Diagnostics

With roughly 1.1 million shares outstanding, the public float is very small, so a few hundred trades can move the indicated price by several cents. Spreads in pre-market sessions can be wide, and the 9.24% move could reverse by the open. Diagnostics developers with limited Revenue usually fund operations through Equity raisings, and any new issuance would dilute a base this small. Average volume, cash, Debt and the 52-week range were not verified in the research window, so none is quoted. A 9.24% move on a base of 1.1 million shares can involve only a few thousand shares changing hands. Post-split price history is not comparable with quotes before November 3, 2026 unless adjusted by the Factor of 4.

Where Things Stand

Bluejay Diagnostics (NASDAQ:BJDX) is 9.24% lower in pre-market trade at USD 2.26, with no catalyst identified in published coverage dated November 9 or 10, 2026. The latest confirmed event is the 1-for-4 reverse split effective November 3, 2026, which cut shares outstanding to about 1.1 million. A market value near USD 2.5 million, calculated, leaves the stock exposed to thin trade, dilution and reversal.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.